INCY Incyte Corp

Price (delayed)

$74

Market cap

$16.46B

P/E Ratio

17.33

Dividend/share

N/A

EPS

$4.27

Enterprise value

$14.06B

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993. Incyte has one drug, ...

Highlights
INCY's net income has soared by 180% year-on-year
INCY's EPS has soared by 177% YoY
The company's quick ratio rose by 4.8% QoQ but it fell by 3.7% YoY

Key stats

What are the main financial stats of INCY
Market
Shares outstanding
222.43M
Market cap
$16.46B
Enterprise value
$14.06B
Valuations
Price to earnings (P/E)
17.33
Price to book (P/B)
4.01
Price to sales (P/S)
4.94
EV/EBIT
22.24
EV/EBITDA
20.24
EV/Sales
4.23
Earnings
Revenue
$3.32B
EBIT
$631.95M
EBITDA
$694.45M
Free cash flow
$664.98M
Per share
EPS
$4.27
Free cash flow per share
$3
Book value per share
$18.44
Revenue per share
$14.98
TBVPS
$22.66
Balance sheet
Total assets
$5.32B
Total liabilities
$1.23B
Debt
$34.19M
Equity
$4.09B
Working capital
$2.7B
Liquidity
Debt to equity
0.01
Current ratio
3.91
Quick ratio
3.68
Net debt/EBITDA
-3.46
Margins
EBITDA margin
20.9%
Gross margin
94.7%
Net margin
28.5%
Operating margin
22%
Efficiency
Return on assets
19.4%
Return on equity
25.4%
Return on invested capital
40.4%
Return on capital employed
14.4%
Return on sales
19%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INCY stock price

How has the Incyte stock price performed over time
Intraday
2.55%
1 week
-4.39%
1 month
-8.05%
1 year
-3.01%
YTD
0.82%
QTD
-2.59%

Financial performance

How have Incyte's revenue and profit performed over time
Revenue
$3.32B
Gross profit
$3.14B
Operating income
$731.39M
Net income
$945.01M
Gross margin
94.7%
Net margin
28.5%
INCY's net income has soared by 180% year-on-year
The net margin has soared by 130% year-on-year but it is down by 5% since the previous quarter
Incyte's operating income has soared by 70% YoY and by 18% from the previous quarter
INCY's operating margin is up by 39% year-on-year and by 11% since the previous quarter

Growth

What is Incyte's growth rate over time

Valuation

What is Incyte stock price valuation
P/E
17.33
P/B
4.01
P/S
4.94
EV/EBIT
22.24
EV/EBITDA
20.24
EV/Sales
4.23
INCY's EPS has soared by 177% YoY
INCY's P/E is 15% below its last 4 quarters average of 20.5
The stock's price to book (P/B) is 48% less than its 5-year quarterly average of 7.7 and 9% less than its last 4 quarters average of 4.4
INCY's equity is up by 39% year-on-year and by 6% since the previous quarter
INCY's P/S is 40% below its 5-year quarterly average of 8.3 and 7% below its last 4 quarters average of 5.3
Incyte's revenue has increased by 22% YoY and by 7% from the previous quarter

Efficiency

How efficient is Incyte business performance
INCY's return on assets has surged by 106% year-on-year but it is down by 6% since the previous quarter
The ROE has soared by 100% YoY but it has contracted by 7% from the previous quarter
INCY's ROS is up by 27% YoY and by 3.3% QoQ
The ROIC has increased by 6% YoY

Dividends

What is INCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INCY.

Financial health

How did Incyte financials performed over time
Incyte's total assets has increased by 36% YoY and by 5% from the previous quarter
INCY's total liabilities is up by 27% year-on-year and by 3.6% since the previous quarter
The debt is 99% smaller than the equity
INCY's equity is up by 39% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.